drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Allogeneic, banked Epstein–Barr virus–specific T lymphocytes engineered to express a CD30-directed chimeric antigen receptor (CAR); binds CD30 on tumor cells to trigger T-cell activation and cytotoxicity, while the native EBV-specific TCR enables recognition of EBV antigens in EBV+ tumors, supporting persistence/expansion and dual targeting.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic EBV-specific T lymphocytes engineered to express a CD30-directed chimeric antigen receptor. CAR engagement of CD30 on tumor cells triggers T-cell activation and cytotoxic killing of CD30+ malignant cells, while the native EBV-specific TCR enables recognition of EBV antigens in EBV+ tumors, supporting persistence/expansion and dual targeting.
drug_name
CD30.CAR-EBVST cells
nct_id_drug_ref
NCT04952584